Sign Up Today and Learn More About Celaid Therapeutics Stock
Invest in or calculate the value of your shares in Celaid Therapeutics or other pre-IPO companies through EquityZen's platform.
Celaid Therapeutics Stock
Celaid Therapeutics is a biotech company that develops cell therapies for blood cancer, intractable blood diseases, and genetic disorders.
About Celaid Therapeutics Stock
Founded
2020
Industries
Software, Artificial Intelligence, Data and Analytics
Celaid Therapeutics Press Mentions
Stay in the know about the latest news on Celaid Therapeutics
Celaid Therapeutics, a University of Tokyo/Tsukuba University Spin-off Engaged in Hematopoietic Stem Cell Therapy, Raises Over ¥1 Billion in Series B to Advance U.S. Clinical Trials
thebridge • Oct 10, 2025
Qualcomm acquires Arduino to deepen its push into robotics
techstartups • Oct 09, 2025
Top Startup and Tech Funding News – October 7, 2025
techstartups • Oct 09, 2025
Celaid Therapeutics Raises JPY 1.055 Billion (USD 7.2 Million) in the First Close of its Series B Financing
en • Oct 09, 2025
EvenUp raises $150M series E funding at $2B valuation to redefine personal injury law with AI
techstartups • Oct 08, 2025
Celaid Therapeutics Management
Leadership team at Celaid Therapeutics
Co-Founder, President, and CEO
Nobuyuki Arakawa
Co-Founder, Chairman, and Chief Scientific Officer
Motoo Watanabe
Join now and verify your accreditation status to gain access to:
- Celaid Therapeutics Current Valuation
- Celaid Therapeutics Stock Price
- Celaid Therapeutics Management
- Available deals in Celaid Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Celaid Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Celaid Therapeutics Revenue and Financials
- Celaid Therapeutics Highlights
- Celaid Therapeutics Business Model
- Celaid Therapeutics Risk Factors
- Celaid Therapeutics Research Report from SACRA Research
Trading Celaid Therapeutics Stock
How to invest in Celaid Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Celaid Therapeutics through EquityZen funds. These investments are made available by existing Celaid Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Celaid Therapeutics stock?
Shareholders can sell their Celaid Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 400K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 49K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."